ChromaDex (NASDAQ:CDXC) Shares Pass Above 200-Day Moving Average - What's Next?

ChromaDex Co. (NASDAQ:CDXC - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.38 and traded as high as $5.52. ChromaDex shares last traded at $5.26, with a volume of 554,195 shares changing hands.

Analyst Ratings Changes

Several research firms have recently commented on CDXC. StockNews.com lowered ChromaDex from a "strong-buy" rating to a "buy" rating in a research report on Friday, January 3rd. Roth Mkm raised their target price on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Finally, HC Wainwright increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, November 4th.

ChromaDex Stock Up 3.4 %

The firm has a market cap of $415.52 million, a PE ratio of 544.54 and a beta of 2.21. The business has a 50-day moving average price of $6.41 and a two-hundred day moving average price of $4.38.

ChromaDex (NASDAQ:CDXC - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $25.58 million during the quarter, compared to analysts' expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same quarter last year, the business posted ($0.01) EPS. On average, equities research analysts predict that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business's stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.64% of the company's stock.

Institutional Investors Weigh In On ChromaDex

Institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Formulas purchased a new stake in shares of ChromaDex in the fourth quarter valued at about $25,000. The Manufacturers Life Insurance Company purchased a new position in ChromaDex in the 2nd quarter valued at approximately $31,000. Merriman Wealth Management LLC acquired a new position in shares of ChromaDex during the 2nd quarter worth $32,000. FMR LLC purchased a new stake in shares of ChromaDex in the third quarter valued at about $55,000. Finally, Marshall Wace LLP acquired a new stake in ChromaDex during the 2nd quarter valued at $56,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.